{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-23-000033","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.052426+00:00","generated_at":"2026-06-09T23:25:49.734386+00:00","sec_items":["7.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Moderna reaffirms FY2023 COVID-19 vaccine revenue guidance of $6-8B; provides scenario-based range","bullets":["Full-year 2023 COVID-19 vaccine revenue guidance unchanged at $6B-$8B.","If U.S. market is ~50M doses, expects to be in bottom half of range.","If U.S. market is ~100M doses, expects to be in top half of range.","Too early to project; better visibility after October vaccination trends.","Will provide an update at the November 2 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-23-000033","json":"https://secwatch.observer/filing/0001682852-23-000033.json","markdown":"https://secwatch.observer/filing/0001682852-23-000033.md","text":"https://secwatch.observer/filing/0001682852-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000033/0001682852-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000033/mrna-20231016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:25:49.734386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}